Biogen (BIIB) entered into a definitive agreement to acquire Massachusetts-based Alcyone Therapeutics. As part of an existing partnership with ...

The purchase gives Biogen full access to an implantable device designed to help patients avoid the repeat lumbar punctures required for medicines like Spinraza.

From left: Myosana CEO Matthew Lumley, with co-founders Stanley Froehner and Nick Whitehead. (Myosana and UW Photos) The news: Myosana Therapeutics, a Seattle startup developing gene therapy ...

- Publication in Human Gene Therapy provides rationale for the use of microdystrophin expression levels as a surrogate endpoint reasonably likely to predict clinical benefit for AAV gene therapy ...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, a clinical-stage biopharmaceutical company developing orally bioavailable, small molecule therapies for musculoskeletal diseases, today ...

Leading KOLs to discuss the unmet needs and current treatment landscapes of idiopathic inflammatory myopathy (IIM), ...

TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)--Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative products for the treatment of rare genetic diseases ...

Dystroglycan, a muscle cell receptor whose dysfunction causes muscular dystrophy, actually has a critical role in brain development, researchers have discovered. Researchers at Stony Brook University ...

The contribution of selected physical development and muscular strength measures to general motor performance capacity was investigated in 55 seven to twelve year old boys. The physical development ...